Is Altimmune, Inc. (ALT) a Buy, Sell, or Hold?
Altimmune, Inc.
NASDAQ:ALT
$2.985 USD
$0.05 (1.88%)
- Volume
- 1.69M
- Average Volume
- 4.41M
- Market Capitalization
- $263.45M
- P/E Ratio
- -3.21
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $6.44
- Year Low
- $2.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $29.56
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jerome Benedict Durso |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALT |
| CUSIP | 02155H200 |
| CIK | 0001326190 |
| Web | https://altimmune.com |
| Phone | 240 654 1450 |
| Currency | USD |
| Employees | 57 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.13 |
| Payout Ratio | 0.00 |
| Current Ratio | 29.56 |
| Quick Ratio | 29.56 |
| Cash Ratio | 8.62 |
Sales & Book Value
| Annual Sales | $41000 |
| Price / Sales | 7318.00 |
| Cash Flow | -0.58 |
| Price / Cash Flow | -3.68 |
| Price / Book | 1.31 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $2.50 |
| Forecast Upside/Downside | -70.15% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1 |
| Trailing P/E Ratio | -3.21 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-88.09M |
| Net Margin | -253002.78% |
| Pretax Margin | -253002.78% |
| Return on Equity | -42.57% |
| Return on Assets | -27.14% |
Financials Score
| AltmanZ Score | 0.53 |
| Piotroski Score | 3.00 |
| Working Capital | 323.35M |
| Total Assets | 335.63M |
| Ebit | -88.38M |
| Market Cap | 262.42M |
| Total Liabilities | 51.64M |
Poll Results
About Altimmune, Inc. (NASDAQ:ALT) Stock
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corpor ... ate headquarters in Gaithersburg, Maryland.
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
2026-07-07 10:16:06
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes.
2026-06-29 04:00:00
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
2026-06-26 06:01:05
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
2026-06-25 09:41:16
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
2026-06-12 12:31:09
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
2026-06-10 10:32:28
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
2026-06-10 09:05:26
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company's focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, or MASH.
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
2026-06-08 13:11:29
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
Frequently Asked Questions
-
What is the current Altimmune, Inc. (ALT) stock price?
-
Altimmune, Inc.(NASDAQ:ALT) stock price is $2.985 in the last trading session. During the trading session, ALT stock reached the peak price of $6.44 while $2.56 was the lowest point it dropped to. The percentage change in ALT stock occurred in the recent session was 1.88% while the dollar amount for the price change in ALT stock was $0.05.
-
ALT's industry and sector of operation?
-
The NASDAQ listed ALT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALT?
-
Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller
Christophe Arbet-Engels | Chief Medical Officer
Jerome Benedict Durso | Chairman, CEO & President
Bertrand Georges | Chief Technology Officer
Raymond Jordt | Chief Business Officer -
How many employees does ALT have?
-
Number of ALT employees currently stands at 57. ALT operates from 910 Clopper Road, Gaithersburg, MD 20878, US.
-
Link for ALT official website?
-
Official Website of ALT is: https://altimmune.com
-
How do I contact ALT?
-
ALT could be contacted at phone #240 654 1450 and can also be accessed through its website. ALT operates from 910 Clopper Road, Gaithersburg, MD 20878, US.
-
How many shares of ALT are traded daily?
-
The average number of ALT shares traded daily for last 3 months was 4.41M.
-
What is the market cap of ALT currently?
-
The market value of ALT currently stands at $263.45M with its latest stock price at $2.985